



DT03 PCT/PTO 14 FEB 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 10, 2005

Signature: 

(Jeffrey S. Sharp)

Docket No.: 27656/40760
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Elias GHANEM et al.

Application No.: 10/518,610

Confirmation No.: N/A

Filed: December 23, 2004

Art Unit: N/A

For: DRUG TRANSPORT
AND DELIVERY SYSTEM

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A summary/abstract translation of the non-English language reference (FR 2,094,175) is enclosed. With respect to the Abstract translation of this reference the Examiner's attention is directed to a difference in the structure of the compound described in the French language description at page 1 from those of the French language claims. Specifically, the formula of

p-F-phenylalanyl (coupled to glycyl) on page 1 is different from the formula in the claims and from the description at page 2 of the French language description which refers to p-fluoro-L-phenylalanyl-glycyl.

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 27656/40760.

A duplicate copy of this paper is enclosed.

Respectfully submitted,


MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
312-474-6300

By:



Jeffrey S. Sharp
Registration No. 31,879
Attorney for Applicants

February 10, 2005



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/518,610
Filing Date	December 23, 2004
First Named Inventor	Elias Ghanem
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	27656/40760

Sheet	1	of	1
-------	---	----	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A	FR-2.094.175	02-04-1972	Instituto Sieroterapico Milanese		X
	B	GB-1 329 869	12-09-1973	De Barbieri A		
	C	WO-WO 99/02177	01-21-1999	Peptichemio AG		
	D	WO-WO 00/31119	06-02-2000	Peptichemio AG		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	E	Weisz et al., "Acidic Coupling And Aminolytic TFA Cleavage Approaches In A New Synthesis Of An L-m-Sarcosylsin Containing Antitumor Tripeptide Ester," Tetrahedron Letters, Vol. 37, No. 5, Pages 563-566, 1996.	
	F	K. Dierickx et al., "Study Of L-Prolyl-M-L-Sarcosyl-L-P-Fluorophenylalanine-Ethylester (PSF) As A New Anticancer Drug Based On A Novel Drug Specific Delivery," Free University of Brussels, J. Bordet-Institute, L.O.C.E., Belgium, Dated 10-2003, Page 24.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Application No. (if known): 10/518,610

Attorney Docket No.: 27656/40760

**Certificate of Mailing under 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on February 10, 2005
Date

A handwritten signature in black ink, appearing to read "Jeffrey S. Sharp".

Signature

Jeffrey S. Sharp

Typed or printed name of person signing Certificate

31,879

Registration Number, if applicable

(312) 474-9578

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (6 References) (1 page)
Information Disclosure Statement